Sabby Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Sabby Management’s Portfolio BXRX Stock Details BXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,981	Closed	-$108K	–	140
2022 Q3	$108K	Buy	10,981 +9,802	+831%	+$228K	0.14%	78
2022 Q2	$40K	Buy	1,179 +706	+149%	+$33K	0.03%	106
2022 Q1	$33K	Buy	+473	New	+$87.3K	﹤0.01%	135
2020 Q2	–	Sell	-267	Closed	-$1.28M	–	138
2020 Q1	$927K	Buy	+267	New	+$2.52M	0.39%	26

Other funds holding BXRX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sittner & Nelson Eugene, Oregon $274M AUM 22.46% 1-Year Est. Return

Sabby Management's BXRX Position: Q4 2022 in Review

Sabby Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2022, closing a stake of 10,981 shares — an estimated $108K sold.

Sabby Management first reported a position in BXRX in Q1 2020 and held it in 4 quarters. The position peaked at $927K in Q1 2020. 10 funds tracked by Wall St. Rank hold BXRX as of Q4 2022.

Sabby Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Sabby Management sold 10,981 Baudax Bio, Inc. Common Stock shares in Q4 2022, an estimated $108K.
Sabby Management first reported a position in Baudax Bio, Inc. Common Stock in Q1 2020 and held it in 4 quarters.
Sabby Management's Baudax Bio, Inc. Common Stock position peaked at $927K in Q1 2020.
10 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2022.

Based on Sabby Management's 13F filing for Q4 2022, filed 14 Feb 2023.